FDAnews Drug Daily Bulletin
Nov. 7, 2012 | Vol. 9 No. 219
Pharma Blog Watch
The Ex(clusivity) Factor (Drug Wonks Blog)
“Rather than speculating as to where the FDA may go in a post-PDUFA V world, it’s important to focus on where it has already gone,” blogger Peter Pitts writes. For one, the FDA has established a new review board within CDER — the CDER Exclusivity Board — tasked to help the agency make consistent findings on whether products should be granted periods of marketing exclusivity. “The board generally meets once or twice a month. Members review written submissions from sponsors and board members participate in meetings with sponsors regarding exclusivity determinations for their products,” Pitts writes.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.